Nrf2 activation putatively mediates clinical benefits of low-dose radiotherapy in COVID-19 pneumonia and acute respiratory distress syndrome (ARDS): Novel mechanistic considerations

Novel mechanistic insights are discussed herein that link a single, nontoxic, low-dose radiotherapy (LDRT) treatment (0.5–1.0 Gy) to (1) beneficial subcellular effects mediated by the activation of nuclear factor erythroid 2-related transcription factor (Nrf2) and to (2) favorable clinical outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Calabrese, Edward J., Kozumbo, Walter J., Kapoor, Rachna, Dhawan, Gaurav, Lara, Pedro C., Giordano, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080499/
https://www.ncbi.nlm.nih.gov/pubmed/33932453
http://dx.doi.org/10.1016/j.radonc.2021.04.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080499/
https://www.ncbi.nlm.nih.gov/pubmed/33932453
http://dx.doi.org/10.1016/j.radonc.2021.04.015

Ejemplares similares